Earth Science Tech Inc. (OTCMKTS:ETST) has shared a new update regarding its cannabidiol (“CBD”) patents. The biotech company says that it is ready to launch its two CBD-based nutraceutical formulas. They include a neuron protector and a breast protector. However, there is so much that is yet to hit the public domain as explained by ETST president and CEO Nickolas Tabraue.
Tabraue outlines, “We will provide more details on the progress of these formulas in the near future.” At the same time, the company has also promised to share the way forward regarding its first CBD-based pharmaceutical product.
The use of CBD and will open the doors for the research
For a very long time, the cannabis industry was for the most successful entrepreneurs in history. However, the market is now open to people from all walks of life thanks to the massive expansion. Thus the need for accelerated research activities. Tabraue affirms that research will result in the development of a revolutionary CDB-based pharmaceutical drug. This will give Earth Science Tech an upper hand in spreading its presence globally.
The formulas will undergo an in vitro testing to establish their biological activities. TransBiotech will carry out the testing, which will compare the level of protection of the hemp oil provided by ETST. The comparison will be against the company’s hemp oil with other natural ingredients. Any positive results will increase its current recognition as a world leader in the CBD space.
Earth Science Tech, Inc. offers the highest quality high-grade full spectrum cannabinoid oil
The company’s Chief Science Officer Dr. Michel Aubé claims that they have a much deeper understanding of cannabinoids compared to their competitors. Besides, the company has received an endorsement verifying that CBD is not addictive. Apparently, CBD was previously under schedule 1 drug classification before its recent shift by U.S. Drug Enforcement Agency (DEA). Nonetheless, there are those CBD products, which DEA has maintained that they are controlled substances. Hence they retain their status in the Schedule 1 list
ETST’s core activities include the formulation, marketing, and distribution of CBD oil. It owns four subsidiaries, which are quickly expanding their operations in the pharmaceutical sectors.